entertainment -WSS

entertainment

author：hotspot 2025-10-01 21:33:57 - browse：7

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： App could help diagnose ear infections more accurately — and at home

hotspot

Wikipedia

WSS

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Shifting the focus from loneliness to social health

Baby aspirin cuts fat buildup in liver disease patients, in small study

Change Healthcare can notify patients about the breach, HHS says

Readout Newsletter: Bluebird, CVS, Contineum

Innovation in antibiotics is ailing. 'Brain drain' may kill it

focus

entertainment

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

Baby aspirin cuts fat buildup in liver disease patients, in small study

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Bluebird, CVS, Contineum

Anesthesiologist group: stop taking Ozempic before surgery

With trial win, GSK could get blood cancer drug back on market

Affirmative action in medical school literally saved lives

ASCO: Palliative care found as helpful given virtually as in person

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

UnitedHealth increases loan offers after Change Healthcare outage

focus

Ultragenyx gene therapy for rare liver ailment succeeds in late

Methadone treatment changes are coming. Do they go far enough?

HIV drugs protect against transmission, even in unprotected sex

Orchard's therapy for neuron disease in children wins FDA approval

Gene editing the human germline: What are the risks?

Let's speed up science by embracing open access publishing

entertainment

hotspot

Wikipedia

hotspot